Clinical Trials
5 trialsNCT01605396 2019-03-25
MK-8669-064
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01234857 2017-05-31
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00736970 2015-08-27
Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01295632 2015-08-27
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01220570 2015-01-21
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Merck Sharp & Dohme LLC
Phase 1 Completed